The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Treating and understanding the biology of extramedullary disease in myeloma
Lalit Kumar, MD, MBBS, All India Institute of Medical Sciences, New Delhi, India, discusses the challenges of treating extramedullary disease in multiple myeloma (MM). He highlights the potential of novel therapeutics iberdomide and mezigdomide, and emphasizes the need to understand why extramedullary disease emerges after therapy with CAR-T cells or bispecific antibodies. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
